{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:33:13Z","timestamp":1794720793390,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Effective management of comorbid diabetes and hypertension in patients with chronic kidney disease (CKD) is important for optimal outcomes. However, little is known about this relationship from a health plan perspective. The objective of this study was to evaluate the association of effective management of comorbid diabetes and\/or hypertension with healthcare resource utilization (HCRU) in patients with chronic kidney disease (CKD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study used the Humana Research Database to identify patients with CKD Stage\u2009\u2265\u20093a in 2017. Eligible patients were enrolled in a Medicare Advantage Prescription Drug plan for\u2009\u2265\u200912\u00a0months before and after the index date (first observed evidence of CKD). Patients with end-stage renal disease, kidney transplant, or hospice election preindex were excluded. Recommended comorbid disease management included hemoglobin A1c monitoring; adherence to glucose-lowering, cardiovascular, and angiotensin-converting enzyme inhibitors\/angiotensin receptor blocker medications; and nephrologist\/primary care provider (PCP) visits. HCRU was evaluated for 12\u00a0months postindex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The final cohort of 241,628 patients was 55% female and 77% White, with an average age of 75\u00a0years. Approximately 90% of patients had Stage 3 CKD. Half had both diabetes and hypertension, and most of the remaining half had hypertension without diabetes. Patients meeting the criteria for good disease management, compared with patients not meeting those criteria, were less likely to experience an inpatient hospitalization, by as much as 40% depending on the criterion and the comorbidities present, or an emergency department visit, by as much as 30%. Total monthly healthcare costs were as much as 17% lower.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Management of comorbid diabetes and hypertension in patients with CKD was associated with lower HCRU and costs. Care coordination programs targeting patients with CKD must give careful attention to glucose and blood pressure control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Not applicable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-023-10424-8","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T09:02:29Z","timestamp":1702630949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Managing comorbidities in chronic kidney disease reduces utilization and costs"],"prefix":"10.1186","volume":"23","author":[{"given":"Yong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Cockrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne","family":"Casebeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne W.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insiya","family":"Poonawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"10424_CR1","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021. March 4, 2021. Available at: https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html. Accessed April 4, 2022."},{"key":"10424_CR2","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States. Reviewed September 2021. Accessed April 1, 2022. https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/kidney-disease."},{"key":"10424_CR3","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease (CKD) Surveillance System. July 2021. Only Half of Adults at High Risk of Kidney Failure Know They Have CKD. Accessed April 4, 2022. https:\/\/nccd.cdc.gov\/ckd\/AreYouAware.aspx?emailDate=July_2021."},{"key":"10424_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/5584_2016_84","volume":"956","author":"SM Hamrahian","year":"2017","unstructured":"Hamrahian SM, Falkner B. Hypertension in Chronic Kidney Disease. Adv Exp Med Biol. 2017;956:307\u201325. https:\/\/doi.org\/10.1007\/5584_2016_84.","journal-title":"Adv Exp Med Biol"},{"key":"10424_CR5","unstructured":"National Kidney Foundation. Diabetes and Chronic Kidney Disease. Updated January 2016. Accessed April 1, 2022: https:\/\/www.kidney.org\/news\/newsroom\/factsheets\/Diabetes-And-CKD."},{"issue":"3","key":"10424_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7326\/m20-5938%m33166222","volume":"174","author":"Diabetes Management in Chronic Kidney Disease","year":"2021","unstructured":"Diabetes Management in Chronic Kidney Disease. Synopsis of the 2020 KDIGO Clinical Practice Guideline. Ann Intern Med. 2021;174(3):385\u201394. https:\/\/doi.org\/10.7326\/m20-5938%m33166222.","journal-title":"Ann Intern Med"},{"key":"10424_CR7","unstructured":"The Kidney Disease: Improving Global Outcomes organization. KDIGO Guidelines. Accessed April 4, 2022: https:\/\/kdigo.org\/guidelines\/."},{"issue":"1","key":"10424_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40842-015-0001-9","volume":"1","author":"AJ Hahr","year":"2015","unstructured":"Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol. 2015;1(1):2. https:\/\/doi.org\/10.1186\/s40842-015-0001-9.","journal-title":"Clin Diabetes Endocrinol."},{"issue":"14","key":"10424_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/nejm199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386. https:\/\/doi.org\/10.1056\/nejm199309303291401.","journal-title":"N Engl J Med"},{"key":"10424_CR10","doi-asserted-by":"publisher","unstructured":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47(6):1703\u201320. https:\/\/doi.org\/10.1038\/ki.1995.236","DOI":"10.1038\/ki.1995.236"},{"issue":"10","key":"10424_CR11","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/diacare.23.10.1478","volume":"23","author":"SR Levin","year":"2000","unstructured":"Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000;23(10):1478\u201385. https:\/\/doi.org\/10.2337\/diacare.23.10.1478.","journal-title":"Diabetes Care."},{"issue":"10","key":"10424_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","volume":"172","author":"SG Coca","year":"2012","unstructured":"Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172(10):761\u20139. https:\/\/doi.org\/10.1001\/archinternmed.2011.2230.","journal-title":"Arch Intern Med"},{"issue":"4","key":"10424_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","volume":"79","author":"D Pugh","year":"2019","unstructured":"Pugh D, Gallacher PJ, Dhaun N. Management of Hypertension in Chronic Kidney Disease. Drugs. 2019;79(4):365\u201379. https:\/\/doi.org\/10.1007\/s40265-019-1064-1.","journal-title":"Drugs"},{"key":"10424_CR14","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease Initiative. Chronic Kidney Disease Basics. Updated February 28, 2022. Accessed April 1, 2022: https:\/\/www.cdc.gov\/kidneydisease\/basics.html."},{"issue":"2","key":"10424_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjmed.2015.08.025","volume":"129","author":"JA Vassalotti","year":"2016","unstructured":"Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. Am J Med. 2016;129(2):153-162.e7. https:\/\/doi.org\/10.1016\/j.amjmed.2015.08.025.","journal-title":"Am J Med"},{"issue":"3","key":"10424_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/193229680900300302","volume":"3","author":"AW Lyon","year":"2009","unstructured":"Lyon AW, Higgins T, Wesenberg JC, Tran DV, Cembrowski GS. Variation in the frequency of hemoglobin A1c (HbA1c) testing: population studies used to assess compliance with clinical practice guidelines and use of HbA1c to screen for diabetes. J Diabetes Sci Technol. 2009;3(3):411\u20137. https:\/\/doi.org\/10.1177\/193229680900300302.","journal-title":"J Diabetes Sci Technol"},{"issue":"9","key":"10424_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"1","key":"10424_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004.","journal-title":"Med Care"},{"issue":"11","key":"10424_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"12","key":"10424_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/s0895-4356(00)00256-0","volume":"53","author":"CN Klabunde","year":"2000","unstructured":"Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258\u201367. https:\/\/doi.org\/10.1016\/s0895-4356(00)00256-0.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10424_CR21","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.2215\/cjn.11030919","volume":"14","author":"LA Tomlinson","year":"2019","unstructured":"Tomlinson LA, Clase CM. Sex and the Incidence and Prevalence of Kidney Disease. Clin J Am Soc Nephrol. 2019;14(11):1557\u20139. https:\/\/doi.org\/10.2215\/cjn.11030919.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10424_CR22","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s11606-020-06272-5","volume":"36","author":"R Gupta","year":"2021","unstructured":"Gupta R, Skootsky SA, Kahn KL, et al. A System-Wide Population Health Value Approach to Reduce Hospitalization Among Chronic Kidney Disease Patients: an Observational Study. J Gen Intern Med. 2021;36(6):1613\u201321. https:\/\/doi.org\/10.1007\/s11606-020-06272-5.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"10424_CR23","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1681\/asn.2017121276","volume":"29","author":"HH Liu","year":"2018","unstructured":"Liu HH, Zhao S. Savings Opportunity from Improved CKD Care Management. J Am Soc Nephrol. 2018;29(11):2612\u20135. https:\/\/doi.org\/10.1681\/asn.2017121276.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10424_CR24","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.37765\/ajmc.2020.43491","volume":"26","author":"S Annavarapu","year":"2020","unstructured":"Annavarapu S, Ghosh S, Li Y, Moretz C, Shetty S, Prewitt T. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations. Am J Manag Care. 2020;26(6):e166\u201371. https:\/\/doi.org\/10.37765\/ajmc.2020.43491.","journal-title":"Am J Manag Care"},{"issue":"6","key":"10424_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/13696998.2017.1288127","volume":"20","author":"RB McQueen","year":"2017","unstructured":"McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ. Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. 2017;20(6):585\u201391. https:\/\/doi.org\/10.1080\/13696998.2017.1288127.","journal-title":"J Med Econ"},{"issue":"7","key":"10424_CR26","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1681\/asn.2019121308","volume":"31","author":"GA Nichols","year":"2020","unstructured":"Nichols GA, Ustyugova A, D\u00e9ruaz-Luyet A, O\u2019Keeffe-Rosetti M, Brodovicz KG. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure. J Am Soc Nephrol. 2020;31(7):1594\u2013601. https:\/\/doi.org\/10.1681\/asn.2019121308.","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10424_CR27","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953.","journal-title":"N Engl J Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-10424-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-023-10424-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-023-10424-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T09:04:52Z","timestamp":1702631092000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-023-10424-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10424"],"URL":"https:\/\/doi.org\/10.1186\/s12913-023-10424-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Humana Healthcare Research Human Subject Protection Office (HHR HSPO) used the US Department of Health and Human Services regulations 45 CFR 46 and the Office of Human Research Protections Guidance on Coded Private Information or Specimens Use in Research, Guidance (2008) to grant an informed consent waiver because it was determined this study did not constitute human subjects research and did not require institutional review board oversight. The decision was based on the determination that the investigation involved only analysis of coded information, and the investigators could not readily identify the individuals from which the information was derived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Humana Inc. and\/or Humana Healthcare Research or were employed by Humana Inc. at the time of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1418"}}